Precigen Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Public

  • Employees
  • 202

Employees

  • Stock Symbol
  • PGEN

Stock Symbol

  • Investments
  • 27

  • Share Price
  • $1.63
  • (As of Wednesday Closing)

Precigen General Information

Description

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 20358 Seneca Meadows Parkway
  • Germantown, MD 20876
  • United States
+1 (301) 000-0000

Precigen Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Precigen Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.63 $1.65 $0.84 - $1.93 $413M 252M 862K -$0.39

Precigen Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 305,175 267,189 336,110 845,918
Revenue 5,439 6,225 26,909 14,267
EBITDA (93,855) (92,463) (62,560) (78,622)
Net Income (96,908) (95,904) 28,317 (92,166)
Total Assets 134,847 151,043 215,977 359,856
Total Debt 6,705 7,097 51,420 190,074
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Precigen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Precigen‘s full profile, request access.

Request a free trial

Precigen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulat
Drug Discovery
Germantown, MD
202 As of 2023
00000
000000000 00000

000000

a aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
0000000000000
Saint-Herblain, France
000 As of 0000
00000
00000000 00000

0000 0

xercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute i
0000000000000
Shanghai, China
00000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Precigen Competitors (42)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Valneva Formerly VC-backed Saint-Herblain, France 000 00000 00000000 00000
WuXi AppTec Formerly PE-Backed Shanghai, China 00000 00.000 000000000 00.000
Codexis Formerly VC-backed Redwood City, CA 000 00000 000000000000 00000
Aclaris Therapeutics Formerly VC-backed Wayne, PA 00 00000 000000000 00000
Cytovance Biologics Formerly PE-Backed Oklahoma City, OK 000 0000 000000&0 0000
You’re viewing 5 of 42 competitors. Get the full list »

Precigen Patents

Precigen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220282282-A1 Buffer solutions for electroporation Pending 26-Feb-2021 00000000 0
CA-3205128-A1 Buffer solutions for electroporation Pending 26-Feb-2021 000000000
AU-2022226284-A1 Buffer solutions for electroporation Pending 26-Feb-2021 000000000
EP-4297863-A1 Buffer solutions for electroporation Inactive 26-Feb-2021 00000000
AU-2022226284-A9 Buffer solutions for electroporation Pending 26-Feb-2021 A61K9/08
To view Precigen’s complete patent history, request access »

Precigen Executive Team (41)

Name Title Board Seat
Helen Sabzevari Ph.D President, Chief Executive Officer & Board Member
Pieter Rottiers Ph.D Chief Executive Officer for Precigen ActoBio
Harry Thomasian Jr. Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Rutul Shah Chief Operating Officer, Operations
Lothar Steidler Ph.D Chief Technology Officer for Precigen ActoBio
You’re viewing 5 of 41 executive team members. Get the full list »

Precigen Board Members (13)

Name Representing Role Since
Cesar Alvarez JD Self Board Member 000 0000
Dean Mitchell Self Board Member 000 0000
Fred Hassan Self Board Member 000 0000
Helen Sabzevari Ph.D Precigen President, Chief Executive Officer & Board Member 000 0000
James Turley Self Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Precigen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Precigen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Precigen‘s full profile, request access.

Request a free trial

Precigen Investments & Acquisitions (27)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Genomatix 24-Oct-2018 0000000000 Biotechnology
Oragenics 09-Nov-2017 0000 00000 00.00 Pharmaceuticals
Genvec 16-Jun-2017 0000000000 000.00 Pharmaceuticals 000000 00
Genten Therapeutics 03-Oct-2016 00000 0000 0000 Biotechnology
Intrexon T1D Partners 04-Apr-2016 Joint Venture Drug Discovery 000000 00
You’re viewing 5 of 27 investments and acquisitions. Get the full list »

Precigen Subsidiaries (4)

Company Name Industry Location Founded
Codexis Laboratories Hungary Biotechnology Budapest, Hungary 2008
Eleszto Genetika Other Pharmaceuticals and Biotechnology Budapest, Hungary 0000
Oxitec Environmental Services (B2B) Abingdon, United Kingdom 0000
Medistem Biotechnology San Diego, CA
To view Precigen’s complete subsidiaries history, request access »

Precigen ESG

Risk Overview

Risk Rating

Updated December, 01, 2023

30.59 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,216

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 405

Rank

00.00

Percentile

To view Precigen’s complete esg history, request access »

Precigen Exits (9)

Company Name Exit Date Exit Type Exit Size Status Buyers
Oragenics 09-Nov-2017 0000 0000000000 00.00 Completed
  • 00000000
Genten Therapeutics 03-Oct-2016 00000 00000 00 0000 Completed
  • 2 buyers
Enviroflight 25-Feb-2016 000000000000000000 Completed
  • 2 buyers
Thrive Agrobiotics 12-Jan-2016 00000 (0000000000) Completed
  • 2 buyers
Okanagan Specialty Fruits 20-Apr-2015 Merger/Acquisition 000.00 Completed
You’re viewing 5 of 9 exits. Get the full list »

Precigen FAQs

  • When was Precigen founded?

    Precigen was founded in 1998.

  • Who is the founder of Precigen?

    Thomas Reed Ph.D and Thomas Reed Ph.D are the founders of Precigen.

  • Who is the CEO of Precigen?

    Helen Sabzevari Ph.D and Pieter Rottiers Ph.D are the CEOs of Precigen.

  • Where is Precigen headquartered?

    Precigen is headquartered in Germantown, MD.

  • What is the size of Precigen?

    Precigen has 202 total employees.

  • What industry is Precigen in?

    Precigen’s primary industry is Drug Discovery.

  • Is Precigen a private or public company?

    Precigen is a Public company.

  • What is Precigen’s stock symbol?

    The ticker symbol for Precigen is PGEN.

  • What is the current stock price of Precigen?

    As of 24-Jul-2024 the stock price of Precigen is $1.63.

  • What is the current market cap of Precigen?

    The current market capitalization of Precigen is $413M.

  • What is Precigen’s current revenue?

    The trailing twelve month revenue for Precigen is $5.44M.

  • Who are Precigen’s competitors?

    Valneva, WuXi AppTec, Codexis, Aclaris Therapeutics, and Cytovance Biologics are some of the 42 competitors of Precigen.

  • What is Precigen’s annual earnings per share (EPS)?

    Precigen’s EPS for 12 months was -$0.39.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »